Amicus Therapeutics Inc (FOLD)
9.73
+0.02
(+0.21%)
USD |
NASDAQ |
Jun 27, 10:21
Amicus Therapeutics Research and Development Expense (Annual): 152.38M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 152.38M |
| December 31, 2022 | 276.68M |
| December 31, 2021 | 272.05M |
| December 31, 2020 | 308.44M |
| December 31, 2019 | 286.38M |
| December 31, 2018 | 270.90M |
| December 31, 2017 | 149.31M |
| December 31, 2016 | 104.79M |
| December 31, 2015 | 76.94M |
| December 31, 2014 | 47.62M |
| December 31, 2013 | 41.94M |
| Date | Value |
|---|---|
| December 31, 2012 | 50.27M |
| December 31, 2011 | 50.86M |
| December 31, 2010 | 39.04M |
| December 31, 2009 | 48.08M |
| December 31, 2008 | 37.76M |
| December 31, 2007 | 31.07M |
| December 31, 2006 | 33.63M |
| December 31, 2005 | 13.65M |
| December 31, 2004 | |
| December 31, 2003 | 4.433M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
152.38M
Minimum
2023
308.44M
Maximum
2020
259.19M
Average
276.68M
Median
2022
Research and Development Expense (Annual) Benchmarks
| Insmed Inc | 571.01M |
| Rhythm Pharmaceuticals Inc | 134.95M |
| Alnylam Pharmaceuticals Inc | 1.004B |
| Cytokinetics Inc | -- |
| InfuSystems Holdings Inc | -- |